BIOA at a glance
BioAge Labs, Inc. (BIOA, SEC CIK 1709941) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding BioAge Labs, Inc. (BIOA) shares worth $239.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Barton Shane on June 30, 2026 of 20,216 shares at $25.19 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.0M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $239.8M · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes from 2025 10-K identified in the provided Risk Factors section
- Clinical-trial failure risk, including unsuccessful preclinical studies, remains central to BGE-102 and APJ programs
- FDA approval risk, including delayed or denied product-candidate approvals, could materially impair commercialization
- Cash-burn risk, with $381.8 million accumulated deficit despite $381.3 million cash, equivalents, and marketable securities
- Customer concentration risk, with one customer representing 100% of revenue and accounts receivable
AI summary of the BIOA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- No earnings-period results or financial metrics available in the supplied section
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss widened to $26.1M from $21.6M, while R&D rose to $24.4M as BGE-102 trials advanced
- QUELL-CV Phase 2 enrolled its first participant, testing 30 mg, 60 mg, and 90 mg doses in approximately 160 adults
Item 5.07: Submission of Matters to a Vote of Security Holders
- Three Class II directors re-elected through 2029: Patrick Enright, James I. Healy, and Rekha Hemrajani
- Patrick Enright received 30,075,928 votes for; James Healy received 25,499,205
AI summaries of BIOA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BIOA
Don't miss the next BIOA filing
- Alerts as it files. A push when BIOA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BIOA, by share count.
- Ask anything. An AI agent that reads every BIOA filing and answers with sources.
BIOA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Barton Shane | M | Jun 30, 2026 | 4,065 | - |
| Barton Shane | M | Jun 30, 2026 | 7,861 | - |
| Barton Shane | M | Jun 30, 2026 | 4,290 | - |
| Barton Shane | M | Jun 30, 2026 | 4,000 | - |
| Barton Shane | M | Jun 30, 2026 | 7,861 | $4.38 |
| Barton Shane | M | Jun 30, 2026 | 4,065 | $4.30 |
| Barton Shane | M | Jun 30, 2026 | 4,000 | $8.39 |
| Barton Shane | Sell | Jun 30, 2026 | 20,216 | $25.19 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $9.0M |
| Operating Income | -$48.4M | -$78.2M | -$92.8M |
| Net Income | - | -$71.1M | -$80.6M |
| Op. Margin | - | - | -1031.5% |
| Net Margin | - | - | -896.1% |
| Balance Sheet | |||
| Total Assets | $25.9M | $358.2M | $294.9M |
| Equity | -$173.4M | $323.1M | $272.1M |
| ROE | - | -22.0% | -29.6% |
| Per Share | |||
| EPS | - | $-6.63 | $-2.24 |
| Cash Flow | |||
| Operating CF | - | -$51.5M | -$81.6M |
| CapEx | $166K | $366K | $719K |
Source: XBRL data in BioAge Labs, Inc. (BIOA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BIOA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $239.8M |
| Q1 2026 | 25 | $140.5M |
| Q4 2025 | 23 | $74.5M |
| Q3 2025 | 21 | $28.1M |
| Q2 2025 | 20 | $16.7M |
| Q1 2025 | 11 | $4.1M |
| Q4 2024 | 7 | $3.1M |
| Q3 2024 | 4 | $10.2M |
- BlackRock+581.3K (+26%)
- Bank of America Corp+196.3K (+319%)
- Vanguard Capital Management LLC+189.3K (+14%)
- Dimensional Fund Advisors+179.6K (+84%)
- State Street Corp+170.6K (+20%)
- Millennium Management−207.8K (-48%)
- Invesco Ltd−48.7K (-28%)
- AQR Capital Management−18.1K (-26%)
- FMR LLC (Fidelity)−6.7K (-4%)
- PNC Financial Services−99 (-5%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 138 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BIOA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | May 8, 2026 | - | Analysis | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BIOA SEC filings: frequently asked questions
Which institutions hold BIOA stock?
As of June 30, 2026, the largest BioAge Labs, Inc. (BIOA) holders among the 13F filers tracked by SignalX were BlackRock ($69.8 million), Vanguard Capital Management LLC ($37.8 million), State Street Corp ($25.0 million), D.E. Shaw & Co ($18.2 million), Vanguard Portfolio Management LLC ($10.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BIOA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24. The figures come from the XBRL data in the 10-K.
What did BIOA report in its latest 8-K?
BioAge Labs, Inc. (BIOA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). No earnings-period results or financial metrics available in the supplied section.
What are the latest BIOA SEC filings?
BioAge Labs, Inc. (BIOA) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on July 1, 2026.
What is BIOA's SEC CIK number?
BioAge Labs, Inc. (BIOA)'s SEC Central Index Key (CIK) is 1709941. EDGAR lists every BIOA filing under that number.
Ask anything about BIOA
The research agent reads BIOA's filings, financials, insider trades and 13F holders, then answers with sources.